SCHEMBL4497426

SCHEMBL4497426

CCOC(=O)C[C@H](O)c1ccc(O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.49
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA7 P43166 2/20 0.49
CA9 Q16790 2/20 0.49
CA14 Q9ULX7 2/20 0.49
ESR1 P03372 2/20 0.49
ESR2 Q92731 2/20 0.49
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 2/20 0.46
HTT P42858 1/20 0.46
TAAR1 Q96RJ0 3/20 0.44
HIF1A Q16665 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
HTR1A P08908 1/20 0.44
THPO P40225 1/20 0.44
BLM P54132 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NMUR2 Q9GZQ4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4497421 1.00 KMT2A (0.49) KMT2ACA12CA1CA2CA7
SCHEMBL20028731 0.85 MAPT (0.47) KMT2AKDM4EALDH1A1HTTTDP1
SCHEMBL4764216 0.85 MAPT (0.47) KMT2AKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL1504155 0.85 ALDH1A1 (0.44) KMT2ACA12CA1CA2CA9
SCHEMBL30935351 0.85 ALDH1A1 (0.44) KMT2ACA12CA1CA2CA9
SCHEMBL13264795 0.84 CA12 (0.51) KMT2ACA12CA1CA2CA7
SCHEMBL295741 0.84 ALDH1A1 (0.53) KMT2AKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL7056947 0.84 ALDH1A1 (0.53) KMT2AKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL10391474 0.84 ALDH1A1 (0.53) KMT2AKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL24643324 0.83 ALOX15 (0.57) KMT2AKDM4EALDH1A1HTTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7498431-B2 Process for the preparation of chiral azetidinones FRAMROZE BOMI PATEL 2009-03-03 US disclosed
US-7498431-B2 Process for the preparation of chiral azetidinones FRAMROZE BOMI PATEL 2009-03-03 US disclosed
US-7498431-B2 Process for the preparation of chiral azetidinones FRAMROZE BOMI PATEL 2009-03-03 US disclosed
US-20070129540-A1 Process for the preparation of chiral azetidinones OPUS ORGANICS PVT LIMITED (IN) 2007-06-07 US disclosed
US-20070129540-A1 Process for the preparation of chiral azetidinones OPUS ORGANICS PVT LIMITED (IN) 2007-06-07 US disclosed
US-20070129540-A1 Process for the preparation of chiral azetidinones OPUS ORGANICS PVT LIMITED (IN) 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129540-A1 Process for the preparation of chiral azetidinones CYP1B1, ALDH7A1, CYP3A5 KMT2A 4551/4885CA12 3334/4885CA1 3251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.